JF
TRVI icon

Jump Financial’s Trevi Therapeutics TRVI Stock Holding History

Jump Financial’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-160,815
Closed -$1.01M – 2175
2025
Q1 		$1.01M Buy
160,815
+139,226
+645% +$664K 0.01% 818
2024
Q4 		$88.9K Buy
+21,589
New +$69.1K ﹤0.01% 1549
2024
Q2 		– Sell
-18,441
Closed -$63.6K – 2275
2024
Q1 		$63.6K Buy
+18,441
New +$41.1K ﹤0.01% 1821
2022
Q4 		– Sell
-42,977
Closed -$66K – 2028
2022
Q3 		$66K Buy
+42,977
New +$141K ﹤0.01% 1483

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Jump Financial's TRVI Position: Q2 2025 in Review

Jump Financial sold out of Trevi Therapeutics (TRVI) in Q2 2025, closing a stake of 160,815 shares — an estimated $1.01M sold.

Jump Financial first reported a position in TRVI in Q3 2022 and held it in 4 quarters. The position peaked at $1.01M in Q1 2025. 153 funds tracked by Wall St. Rank hold TRVI as of Q2 2025.

  • Jump Financial reported no remaining Trevi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jump Financial sold 160,815 Trevi Therapeutics shares in Q2 2025, an estimated $1.01M.
  • Jump Financial first reported a position in Trevi Therapeutics in Q3 2022 and held it in 4 quarters.
  • Jump Financial's Trevi Therapeutics position peaked at $1.01M in Q1 2025.
  • 153 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2025.

Based on Jump Financial's 13F filing for Q2 2025, filed 13 Aug 2025.